Weekly News Round-up – 14/2/20
The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...
5 years agoWeekly News Round-up – 14/2/20
The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...
5 years ago
Weekly News Round-up – 7/2/20
Two big pharma restructures this week,with both GSK and Merck making promises to spin off or divide their existing assets. GSK disappointed some investors with its £2.4 billion plan to separate its consumer health arm and save £700 million a...
5 years agoWeekly News Round-up – 7/2/20
Two big pharma restructures this week,with both GSK and Merck making promises to spin off or divide their existing assets. GSK disappointed some investors with its £2.4 billion plan to separate its consumer health arm and save £700 million a...
5 years ago
Trending Innovations in Cold Chain Processes
As is increasingly known in the pharmaceutical industry, the rise in both trial costs and drug failures has seen a corresponding increase in the need for tight regulations and stricter procedures, to ensure the few successes are not further compromised....
5 years agoTrending Innovations in Cold Chain Processes
As is increasingly known in the pharmaceutical industry, the rise in both trial costs and drug failures has seen a corresponding increase in the need for tight regulations and stricter procedures, to ensure the few successes are not further compromised....
5 years ago
Weekly News Round-up – 31/1/20
With the Chinese Coronavirus dominating the news this week, headlines were a diverse affair: Novartis has backed out of a generic program copying Advair, with the company citing that they could no longer see a way to launch in the...
5 years agoWeekly News Round-up – 31/1/20
With the Chinese Coronavirus dominating the news this week, headlines were a diverse affair: Novartis has backed out of a generic program copying Advair, with the company citing that they could no longer see a way to launch in the...
5 years ago
Proventa’s Weekly Round-up – 10/1/19
Happy new year! It’s a fairly slow week as the sector takes stock and begins to get back, with annual price rises the main event in the news - big pharma has announced its regular price increases for the new...
5 years agoProventa’s Weekly Round-up – 10/1/19
Happy new year! It’s a fairly slow week as the sector takes stock and begins to get back, with annual price rises the main event in the news - big pharma has announced its regular price increases for the new...
5 years ago
Time to invest in CGT: Its Benefits for Pharma
The concept of cell and gene therapy (CGT), wherein scientists and healthcare experts adapt cells and genes to treat illnesses, is nothing new in the life science space. Even the relatively new CRISPR has transformed into a household buzzword over...
5 years agoTime to invest in CGT: Its Benefits for Pharma
The concept of cell and gene therapy (CGT), wherein scientists and healthcare experts adapt cells and genes to treat illnesses, is nothing new in the life science space. Even the relatively new CRISPR has transformed into a household buzzword over...
5 years ago
Single-Use Technologies: Challenges and Solutions
Since their increased popularisation from the mid-1990s, single- and limited-use technologies (collectively SUTs) have changed the field of biomanufacturing. This has been driven partly by the heavy growth of the pharma market, from $162 billion in 2014 to around $270...
5 years agoSingle-Use Technologies: Challenges and Solutions
Since their increased popularisation from the mid-1990s, single- and limited-use technologies (collectively SUTs) have changed the field of biomanufacturing. This has been driven partly by the heavy growth of the pharma market, from $162 billion in 2014 to around $270...
5 years ago
Google – The New Pharmaceutical Regulator?
Last Friday, Google stated in a press release that it would no longer be accepting advertisements for “speculative and experimental medical treatments”, including most stem cell or gene therapies, after observing unscrupulous companies taking advantage of patients through offers of...
5 years agoGoogle – The New Pharmaceutical Regulator?
Last Friday, Google stated in a press release that it would no longer be accepting advertisements for “speculative and experimental medical treatments”, including most stem cell or gene therapies, after observing unscrupulous companies taking advantage of patients through offers of...
5 years ago